AbstractThe clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the treatment of inflammatory bowel diseases (IBD). It has demonstrated impressive efficacy as compared to alternative treatments, allowing for the chance to achieve near-remission and long-term improvement in function and quality of life and to alter the natural history of Crohn's disease (CD) and ulcerative colitis (UC). As a consequence of longer follow-up periods the number of side effects which may be attributed to treatment with biologics is growing significantly. Cutaneous reactions are among the most common adverse reactions. These complications include injection site reactions, cutaneous infections, immune-mediated complications such as ...
International audienceBACKGROUND & AIMS: Psoriasiform and eczematiform lesions are associated with a...
none9Ulcerous rectocolitis and Crohn's disease are the best known forms of inflammatory bowel diseas...
Introduction. The data on the safety profile of anti-tumor necrosis factor (anti-TNF) therapy in rea...
The clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the treatmen...
All drugs currently used for treating patients with inflammatory bowel disease (IBD-including Crohn'...
All drugs currently used for treating patients with inflammatory bowel disease (IBD - including Croh...
The biologic era has greatly improved the treatment of Crohn's disease and ulcerative colitis. Biolo...
Anti-tumor necrosis factor (anti-TNF) drugs such as infliximab, adalimumab, and certolizumab pegol h...
Background: Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis fac...
As anti-tumor necrosis factor alpha (anti-TNFα) agents are progressively being used in various...
Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical ...
Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequent...
BACKGROUND & AIMS:: Psoriasiform and eczematiform lesions are associated with anti-tumor necrosis fa...
Background and Aims: Skin eruptions are prevalent among patients with inflammatory bowel diseases (I...
A subgroup of patients with inflammatory bowel disease (IBD) treated with anti-tumor necrosis factor...
International audienceBACKGROUND & AIMS: Psoriasiform and eczematiform lesions are associated with a...
none9Ulcerous rectocolitis and Crohn's disease are the best known forms of inflammatory bowel diseas...
Introduction. The data on the safety profile of anti-tumor necrosis factor (anti-TNF) therapy in rea...
The clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the treatmen...
All drugs currently used for treating patients with inflammatory bowel disease (IBD-including Crohn'...
All drugs currently used for treating patients with inflammatory bowel disease (IBD - including Croh...
The biologic era has greatly improved the treatment of Crohn's disease and ulcerative colitis. Biolo...
Anti-tumor necrosis factor (anti-TNF) drugs such as infliximab, adalimumab, and certolizumab pegol h...
Background: Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis fac...
As anti-tumor necrosis factor alpha (anti-TNFα) agents are progressively being used in various...
Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical ...
Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequent...
BACKGROUND & AIMS:: Psoriasiform and eczematiform lesions are associated with anti-tumor necrosis fa...
Background and Aims: Skin eruptions are prevalent among patients with inflammatory bowel diseases (I...
A subgroup of patients with inflammatory bowel disease (IBD) treated with anti-tumor necrosis factor...
International audienceBACKGROUND & AIMS: Psoriasiform and eczematiform lesions are associated with a...
none9Ulcerous rectocolitis and Crohn's disease are the best known forms of inflammatory bowel diseas...
Introduction. The data on the safety profile of anti-tumor necrosis factor (anti-TNF) therapy in rea...